SynthesisBMC nephrology2026
Veverimer in treating metabolic acidosis in chronic kidney disease patients: a systematic review and meta-analysis of randomized clinical trials.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney failure (CKD), a common cause of mortality, impacts about 800 million individuals globally. Metabolic acidosis, which occurs in 20% of people with CKD, complicates the course of CKD and increases the possibility of morbidity and mortality in these patients. Veverimer, a promising experimental acid-binding polymer that may be taken orally and has a high capacity, presents a unique method for the management of metabolic acidosis conditions in CKD patients. This study aimed to assess the safety and effectiveness of veverimer compared to placebo by analysing data from randomised controlled trials.
methodsA systematic review and meta-analysis were conducted following PRISMA guidelines. Databases searched included PubMed, Scopus, Web of Science, Embase, clinicaltrials.gov, and Cochrane CENTRAL until April 24th, 2025. Our analysis comprised randomised controlled trials that assessed the impact of veverimer on patients with CKD and metabolic acidosis. Quality assessment was performed using the Joanna Briggs Institute (JBI) assessment.
resultsFour studies met the inclusion criteria. A total of 1083 participants were randomly assigned to receive veverimer, whereas 945 participants were given a placebo. Veverimer was able to significantly increase serum bicarbonate compared to the placebo group (mean difference = 2.90 mmol/L (95% CI: 2.15 to 3.65, p < 0.01)). The adverse events in the veverimer group did not differ significantly from the placebo group. Meta-regression showed that mean age and mean GFR did not have a statistically significant association with the treatment effect. DISCUSSION AND
conclusionIn conclusion, our study offers robust support for the use of veverimer in treating metabolic acidosis, while also identifying areas that require additional investigation. The results of this study may inform future research and clinical practices in managing metabolic acidosis. CLINICAL TRIAL: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.